BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 29535360)

  • 1. miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers.
    Givel AM; Kieffer Y; Scholer-Dahirel A; Sirven P; Cardon M; Pelon F; Magagna I; Gentric G; Costa A; Bonneau C; Mieulet V; Vincent-Salomon A; Mechta-Grigoriou F
    Nat Commun; 2018 Mar; 9(1):1056. PubMed ID: 29535360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer.
    Costa A; Kieffer Y; Scholer-Dahirel A; Pelon F; Bourachot B; Cardon M; Sirven P; Magagna I; Fuhrmann L; Bernard C; Bonneau C; Kondratova M; Kuperstein I; Zinovyev A; Givel AM; Parrini MC; Soumelis V; Vincent-Salomon A; Mechta-Grigoriou F
    Cancer Cell; 2018 Mar; 33(3):463-479.e10. PubMed ID: 29455927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CXCL12α and CXCL12β stimulate the migration of cultured LX-2 hepatic stellate cells].
    Yuan X; Xiao T; Dai F; Yu Y; Lou J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Mar; 31(3):293-6. PubMed ID: 25744829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway.
    Licaj M; Mhaidly R; Kieffer Y; Croizer H; Bonneau C; Meng A; Djerroudi L; Mujangi-Ebeka K; Hocine HR; Bourachot B; Magagna I; Leclere R; Guyonnet L; Bohec M; Guérin C; Baulande S; Kamal M; Le Tourneau C; Lecuru F; Becette V; Rouzier R; Vincent-Salomon A; Gentric G; Mechta-Grigoriou F
    Nat Commun; 2024 Feb; 15(1):1312. PubMed ID: 38346978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenic effects of stromal cell-derived factor-1 (SDF-1/CXCL12) variants in vitro and the in vivo expressions of CXCL12 variants and CXCR4 in human critical leg ischemia.
    Ho TK; Tsui J; Xu S; Leoni P; Abraham DJ; Baker DM
    J Vasc Surg; 2010 Mar; 51(3):689-99. PubMed ID: 20206813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
    Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
    Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.
    Gao Q; Yang Z; Xu S; Li X; Yang X; Jin P; Liu Y; Zhou X; Zhang T; Gong C; Wei X; Liu D; Sun C; Chen G; Hu J; Meng L; Zhou J; Sawada K; Fruscio R; Grunt TW; Wischhusen J; Vargas-Hernández VM; Pothuri B; Coleman RL
    J Exp Med; 2019 Mar; 216(3):688-703. PubMed ID: 30710055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma.
    Li Y; Tian R; Liu J; Li J; Tan H; Wu Q; Fu X
    Front Immunol; 2022; 13():940801. PubMed ID: 36119108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types.
    Kobayashi M; Sawada K; Nakamura K; Yoshimura A; Miyamoto M; Shimizu A; Ishida K; Nakatsuka E; Kodama M; Hashimoto K; Mabuchi S; Kimura T
    J Ovarian Res; 2018 Sep; 11(1):81. PubMed ID: 30219071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer.
    Mieulet V; Garnier C; Kieffer Y; Guilbert T; Nemati F; Marangoni E; Renault G; Chamming's F; Vincent-Salomon A; Mechta-Grigoriou F
    Sci Rep; 2021 Feb; 11(1):4219. PubMed ID: 33603134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twist1 is a key regulator of cancer-associated fibroblasts.
    Lee KW; Yeo SY; Sung CO; Kim SH
    Cancer Res; 2015 Jan; 75(1):73-85. PubMed ID: 25368021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.
    Winterhoff BJ; Maile M; Mitra AK; Sebe A; Bazzaro M; Geller MA; Abrahante JE; Klein M; Hellweg R; Mullany SA; Beckman K; Daniel J; Starr TK
    Gynecol Oncol; 2017 Mar; 144(3):598-606. PubMed ID: 28111004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
    Turcotte M; Spring K; Pommey S; Chouinard G; Cousineau I; George J; Chen GM; Gendoo DM; Haibe-Kains B; Karn T; Rahimi K; Le Page C; Provencher D; Mes-Masson AM; Stagg J
    Cancer Res; 2015 Nov; 75(21):4494-503. PubMed ID: 26363007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
    Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
    Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours.
    Rainczuk A; Rao JR; Gathercole JL; Fairweather NJ; Chu S; Masadah R; Jobling TW; Deb-Choudhury S; Dyer J; Stephens AN
    Int J Cancer; 2014 Feb; 134(3):530-41. PubMed ID: 23873303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-448 negatively regulates ovarian cancer cell growth and metastasis by targeting CXCL12.
    Lv Y; Lei Y; Hu Y; Ding W; Zhang C; Fang C
    Clin Transl Oncol; 2015 Nov; 17(11):903-9. PubMed ID: 26103953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer.
    Wessolly M; Mairinger E; Borchert S; Bankfalvi A; Mach P; Schmid KW; Kimmig R; Buderath P; Mairinger FD
    Front Oncol; 2022; 12():798680. PubMed ID: 35311102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-141 Regulates colonic leukocytic trafficking by targeting CXCL12β during murine colitis and human Crohn's disease.
    Huang Z; Shi T; Zhou Q; Shi S; Zhao R; Shi H; Dong L; Zhang C; Zeng K; Chen J; Zhang J
    Gut; 2014 Aug; 63(8):1247-57. PubMed ID: 24000293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.